Determining if a new cosmetic product, pharmaceutical ingredient, or chemical substance is harmful to humans is a key prerequisite for product safety and consumer protection. Traditionally, skin sensitization testing relied on animal models, but these approaches are expensive, time consuming and raise ethical questions, while only offering limited human relevance and accuracy. SenzaGen has developed a unique, in vitro approach to sensitization testing, combining cell biology and flow cytometry with genomics-based screening and machine learning-assisted classifications
Anna Chérouvrier Hansson leads the business development and sales activities at SenzaGen. With more than 20 years in the life science industry, she has experience from leading projects within pharma, medical device and specialised service companies with focus on delivering superior products and solutions.
Ulrika Mattson is Senior Application Scientist at SenzaGen. She has a long experience of laboratory work and today she leads projects and studies involving SenzaGen’s proprietary technology GARD for assessment of skin and respiratory sensitizers. Ulrika has experience of Tecan’s equipment at SenzaGen’s laboratory.